SyneuRx is developing new drugs on schizophrenia, depression and dementia in order to answer the unmet medical needs in central nervous system (CNS) disorders. Our first few candidate drugs hold great promise to fast track the development process and reach a dominant position in the CNS drug market quickly.

Our competitive advantages include:

      Strong drug efficacy: Innovative, breakthrough, new class of drugs. Strong results from world-leading published studies indicate the effectiveness of the drug is better than any existing drugs. When reach the market, the drugs can be as noteworthy as when Prozac was first introduced for depression, if not more.

        Low development cost: Because there are abundant evidence for safety of our candidate drugs we can reach the clinical development quickly. Cost of clinical trials is also substantially reduced due to Breakthrough Therapy Designation (BTD) and orphan drug status whereas the new drug is also effective for non-orphan common CNS disorders.  The BTD and orphan drug destination promises fast track development for unmet medical need that comes with substantial regulatory and marketing advantage.

   Large market size: There are two BTDs and two orphan therapies granted a potential 7 year market exclusivity. Our drugs, once developed, will be the dominant CNS drugs for the market. There will be little to no rival due to the major patent cliff and scarcity of new CNS drug.

Condition

Phase I

Phase II

Phase III

 

 

 

 

Schizophrenia

SND11 Adolescent Schizophrenia

相關內容

Orphan Drug Designation

 Phase IIb/III 

I
I
I

SND12 Refractory Schizophrenia

問題內容

Orphan Drug Designation, Breakthrough Therapy Designation

 Phase IIb/III 

I
I
I

SND13 Adult Schizophrenia

問題內容

Breakthrough Therapy Designation

 Phase IIb/III 

I
I
I

Condition

Phase I

Phase II

Phase III

 

Dementia

SND14 Early Dementia

問題內容

 Phase IIb/III 

I
I
I

SND51 Dementia & Psychosis Symptoms

問題內容

 Phase II  

I
I
I

Condition

Phase I

Phase II

Phase III

 

Depression

SNG12 Depression & Suicidality

問題內容

 Phase III 

I
I
I

SNA1 Refractory Depression

問題內容

 Phase II 

I
I
I

R & D plans may change

Business development plan

           SyneuRx’ mid to long-term goal is to collaborate with internationally renowned pharmaceutical companies as strategic partners and pursuing development of multiple indications to maximize the market share. We will build up the momentum from R&D to commercialization. Our vision is not not only in improving the illness, but will reduce the stigma and social burden of CNS disorders.